Emergent BioSolutions (EBS) Misses Q3 EPS by 3c, FY Revenue Guidance Beats

Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.55, $0.03 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $173.7 million versus the consensus estimate of $184.1 million.

GUIDANCE:

Emergent BioSolutions sees FY2018 EPS of $770.00-$800.00, versus the consensus of $741.00.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c